Celator Pharmaceuticals

Celator Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies to treat cancer. The company focuses on CombiPlex, a drug ratio technology platform that enables to the development of combination therapies. Its products include CPX-1 (Irinotecan HCI-Floxuridine), a treatment for colorectal cancer; and CPX-351 (Cytarabine-Daunorubicin), a treatment for acute myeloid leukemia (AML). Celator Pharmaceuticals, Inc. was formerly known as Celator Technologies, Inc. The company was founded in 2000 and is headquartered in Princeton, New Jersey.

Celator Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Medical, Biopharma, Health Diagnostics sector. The company focuses on Biotechnology and has secured $46.4B in funding across 264 round(s). With a team of 11-50 employees, Celator Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series D - Celator Pharmaceuticals, raised $20.0M. Discover more about their projects, partnerships, and impact on our platform.